title: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
abstract: BACKGROUND
  A consistent relationship between metabolic syndrome (MS) and myocardial infarction (MI) has been demonstrated. We evaluated the effect of bezafibrate retard, a fibric acid derivative, on the incidence of MI in patients with MS enrolled in the Bezafibrate Infarction Prevention (BIP) study.
  
  
  METHODS
  Patients who displayed at least 3 of the following 5 risk factors were considered to have MS: (1) a fasting glucose level of 110 mg/dL (6.11 mmol/L); (2) a triglyceride level of 150 mg/dL (1.70 mmol/L); (3) a high-density lipoprotein cholesterol level less than 40 mg/dL (<1.04 mmol/L) in men or less than 50 mg/dL (<1.30 mmol/L) in women; (4) a systolic blood pressure of 130 mm Hg or diastolic blood pressure of 85 mm Hg; and (5) a body mass index of 28.0 kg/m(2). The study sample for this post hoc subgroup analyses comprised 1470 patients aged 42 to 74 years. The patients received either 400 mg of bezafibrate retard (740 patients) or placebo (730 patients) once a day. The mean follow-up period was 6.2 years for events and 8.1 years for mortality data.
  
  
  RESULTS
  New MI was recorded in 193 patients: 82 (11.1%) of the 740 patients in the bezafibrate group vs 111 (15.2%) of the 730 patients in the placebo group (P = .02). Bezafibrate was associated with a reduced risk of any MI and nonfatal MI with hazard ratios (HRs) of 0.71 (95% confidence interval [CI], 0.54-0.95) and 0.67 (95% CI, 0.49-0.91), respectively. The cardiac mortality risk tended to be lower in patients taking bezafibrate (HR, 0.74; 95% CI, 0.54-1.03). In 575 patients with augmented features of MS (4-5 risk factors), the remarkable strengthening of cardiac mortality reduction when taking bezafibrate (HR, 0.44; 95% CI, 0.25-0.80) should be noted.
  
  
  CONCLUSIONS
  Bezafibrate reduces the incidence of MI in patients with MS during long-term follow-up.
authors.affiliation: Cardiac Rehabilitation Institute, Neufeld Cardiac Research Institute, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: Alexander
authors.initials: A
authors.lastname: Tenenbaum
authors.forename: Michael
authors.initials: M
authors.lastname: Motro
authors.forename: Enrique Z
authors.initials: EZ
authors.lastname: Fisman
authors.forename: David
authors.initials: D
authors.lastname: Tanne
authors.forename: Valentina
authors.initials: V
authors.lastname: Boyko
authors.forename: Solomon
authors.initials: S
authors.lastname: Behar
mesh_terms: D000328:Adult; D000368:Aged; D001629:Bezafibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000502:physiology; D015992:Body Mass Index; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015994:Incidence; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D000960:Hypolipidemic Agents; D008055:Lipids; D001629:Bezafibrate